Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Nicorette second quarter U.S. sales up 9%, but NicoDerm CQ sales fall 18%.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE NICORETTE SECOND QUARTER SALES INCREASE 9% in the U.S., while sales for NicoDerm CQ fell 18% during the period, SmithKline Beecham said July 21. Helped by the Nicorette nicotine gum increase, the company maintained its 94.4% share of the U.S. OTC smoking cessation market for the quarter. However, U.S. sales for SmithKline's OTC drug products decreased 1% to $517 mil. for the same period.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel